I don't want to over think this but it's at The HF so it's a big position. This recent news release could this become a sell the news event.. instead of garnering new interest? Centrus Energy (LEU) to Start HALEU Production at Piketon Site-- Wed, September 13, 2023 Centrus Energy LEU is set to start production of High-Assay Low-Enriched Uranium (HALEU) at its American Centrifuge Plant in Piketon, OH in October 2023. It will be the first new U.S.-owned uranium enrichment plant to begin production since 1954.
Is TOMI "on discount" yet? I actually thought that one might keep going, the way it acted up there at 1.28 $1.10 now. No friggin volume at all.
Man Cramer sure did go off about the UAW President this A.M. Called him a paper-tiger. He said management should just play the nuclear card and threaten to move all those jobs to Mexico. Yeah right.... like the UAW President would believe that Jim. You don't think Biden might have something to say about that? That would be the most impotent bluff of all time.
Sometimes in my world of TA I will rely on vol analysis. I am going to put a buy on RIVIAN right here-- now there are other technical reasons not to buy for sure! Bunch./ I can list them here in a Master Class if you want.. But just going off vol... this stock is about to make a run into the $30's. THE STOCK FOR NEXT WEEK IS RIVIAN! gba upgrade: RIVN RIVN Rivian Automotive, Inc. $24.11 +0.86(+3.70%)4:00 PM 09/14/23 NASDAQ |$USD |Realtime
Lets see if BJ can get thru $70> Classic pattern double bottom at $65<-- $70 inportant spot May 23' break // Aug 11 Aug 21 Top TA Alert**** BJ BJ BJ's Wholesale Club Holdings, Inc. $69.81 +2.35(+3.48%) 4:00 PM 09/14/23
I'm currently in Baytex Energy ( overweight ), Athabaska Oil ( overweight ), Lucero Energy, Crescent Point ( overweight ), Gear Energy. The route to higher values has been frustrating given the fundamentals are so good. However, the first 3 are threatening to blast out recent highs again. I see Crescent Point and Gear as trades. Lucero I've traded the recent range successfully but the volume suggests it's going to blast through soon imo. Have been in Whitecap, MEG Energy, Cenovus here or there. My small cap gambles in other sectors are pretty lively ( mostly good ), but I'm underwater on a few mining stocks that I'm unloading on strength as appropriate. Silver stocks really have been duds lately; they are so hard to trade really without just living with prolonged downturns.
NINE! Welcome to the action. You are overweight my baby now Crescent Point... Oh how I wish you had just bought with me originally and rode this bad boy... I escaped off and may now look to get back in. Glad you're on board! Small cap trades are very tough I just got manhandled by CTLP.> I may have an idea for you today. Did 19 mil vol go the wrong way? Iovance FDA delay has 'some pretty big silver linings,' says Mizuho » 06:47 IOVA -U.S. Food and Drug Administration Updates Prescription Drug User Fee Act (PDUFA) Action Date for Lifileucel for the Treatment of Advanced Melanoma - Iovance Biotherapeutics, Inc. (IOVA) NasdaqGM - NasdaqGM Real Time Price. 4.6450-0.7900(-14.54%)<--------------- At close: September 14 04:00PM EDT 5.46+0.82(+17.57%)<---------- Pre-Market:- Taking into account yesterdays sell off on this news we are only up 3% this am.... Iovance Biotherapeutics, Inc. Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the U.S. Food and Drug Administration (FDA), because of resource constraints, requires additional time to complete the Priority Review of Iovance’s Biologics License Application (BLA) for lifileucel. The BLA is seeking accelerated approval of lifileucel for patients with advanced melanoma. The FDA extended the new target action date for a decision under the Prescription Drug User Fee Act (PDUFA) to February 24, 2024, but agreed to work with Iovance to expedite the remaining review for a potentially earlier approval date. The FDA recently notified Iovance that they had insufficient resources to review a recent response to an information request for the ongoing BLA review prior to the planned late-cycle review meeting scheduled for September 11, 2023. In a meeting with the FDA held on September 14, 2023, the FDA acknowledged the resource constraints and agreed to work closely with Iovance to expedite the remaining review. The overall BLA process continues under Priority Review with several recent positive status updates. The FDA reiterated there are no major review issues, and there are no plans to hold an advisory committee meeting. In addition, all pre-approval inspections of clinical sites. internal and external manufacturing and testing facilities have been successfully completed. The FDA is also engaged and has expressed no concerns on the status of the TILVANCE-301 confirmatory trial in frontline advanced melanoma, which remains on track to be well underway by the PDUFA date.